Zhi Tong Cai Jing·2026-02-27 02:34Core Viewpoint - CanSino Biologics (06185) reported a significant increase in stock price following the release of its annual performance report, indicating positive market sentiment towards the company's financial results [1] Financial Performance - Total revenue for the year reached 1.068 billion RMB, representing a year-on-year growth of 26.18% [1] - The net profit attributable to the parent company was 27.8727 million RMB, marking a turnaround from a loss to profitability [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with a focus on its first quadrivalent meningococcal conjugate vaccine, Manhaixin, which has shown sustained revenue growth [1] - CanSino Biologics has effectively managed costs and improved operational efficiency, leading to enhanced profitability [1] Operational Efficiency - The company has optimized production and sales coordination, resulting in an increase in gross margin [1] - Overall profitability has significantly improved, achieving a positive net profit for the reporting period [1]